Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »Another Oral Combination Antidiabetic Agent
Dual and triple therapy just got a little easier.
Read More »Real-World Evidence in Support of Continuous Glucose Monitoring
Insulin delivery method or blood glucose monitoring – which is more important?
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Telehealth, Smartphones, Mobile Apps and CGM: Changing The Way We Control Type 2 Diabetes In Adults
Can a virtual diabetes clinic (VDC) improve diabetes care?
Read More »Elevated HbA1c = CVD
The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.
Read More »Best Plan for Patient May Not Be The Recommended Plan
Female, type 1 diabetes for 42 years, 58 years of age, lives with husband and dog. The patient has hypoglycemic unawareness. We regularly readjust her treatment plan and have recommended CGM for this patient on numerous occasions. Still, she refuses, stating her dog wakes her up if and when she has hypoglycemia. She called to let us know her dog passed away....
Read More »Part 3: Innovative Artificial Intelligence (AI) Tool Optimizes Care for T2D Patients
Optimize Clinical Diabetes Management with AI Technology
A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.
In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.
The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »